Filament Health Corp. announced an agreement with the Centre for Addiction and Mental Health (CAMH), Canada's largest mental health teaching hospital and one of the world's leading research centres in the field. Filament will supply CAMH with its natural psilocybin drug candidate for a proposed clinical trial studying the effects of psilocybin for treatment-resistant depression (TRD).

The trial will be funded by the first ever Canadian federal grant to study psilocybin. Treatment-resistant depression (TRD) affects up to a third of all depressed individuals, and results in substantial functional decline and high mortality rates. Current treatment options for TRD, can have either inadequate efficacy, adverse effects, or are difficult to access.

With this trial, CAMH intends to determine whether psychedelic-assisted psychotherapy with psilocybin is a viable alternative treatment, and whether psychedelic effects are necessary for efficacy. The clinical trial application is under review by Health Canada with approval anticipated by January 2023.